2seventy bio, Inc.
TSVT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.03 | 0.03 | -0.02 |
| FCF Yield | -55.83% | -85.89% | -77.86% | -37.49% |
| EV / EBITDA | -3.31 | -1.90 | -2.12 | -2.55 |
| Quality | ||||
| ROIC | -25.33% | -45.84% | -43.88% | -43.53% |
| Gross Margin | 40.41% | 83.15% | 71.34% | 76.91% |
| Cash Conversion Ratio | 1.48 | 0.77 | 0.93 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | -25.48% | 22.57% | -28.29% | 7.17% |
| Free Cash Flow Growth | 52.58% | 30.48% | -14.72% | -151.64% |
| Safety | ||||
| Net Debt / EBITDA | -1.75 | -0.88 | -0.79 | -0.51 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 1.92 | -0.11 |
| Cash Conversion Cycle | 57.94 | -81.29 | 173.13 | -3,369.88 |